NAGE — Niagen Bioscience, Inc.
NASDAQ · Healthcare · Biotechnology
$3.23
+$0.03 (+0.78%)
Niagen Bioscience, Inc. (NAGE) is a biotechnology company listed on NASDAQ. It is led by Robert N. Fried, based in 10900 Wilshire Blvd, Los Angeles, CA, United States, 90024, with about 104 employees. Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Latest reported NAGE revenue for 2025-09-30 was $34.0M. Net income was $4.6M. Revenue was up 9.2% from 2025-06-30 to 2025-09-30. NAGE currently screens at market cap $836.5M and trailing P/E 59.0.
Use this NAGE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NAGE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NAGE SEC filings page. Lician reads the product cache first so this HTML stays unique to Niagen Bioscience, Inc. even when a live quote feed is slow.
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
NAGE Key Statistics
Market Cap
$836.53M
Volume
183,719
Previous Close
$3.21
Day Range
$3.20 – $3.30
P/E Ratio
59.00
EPS
$0.11
Revenue
$99.60M
Net Income
$8.55M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+19.2%
Profit Margin
8.6%
Employees
104
NAGE Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $99.60M | $83.57M | $72.05M | $67.45M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $8.55M | -$4.94M | -$16.54M | -$27.13M |
| EPS (Diluted) | $0.11 | -$0.07 | -$0.24 | -$0.40 |
Total Assets
$68.28M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$44.50M
Operating Cash Flow
$12.11M
Free Cash Flow
$0.00
Niagen Bioscience, Inc. Company Information
- CEO & Director
- Robert N. Fried
- Headquarters
- 10900 Wilshire Blvd, Los Angeles, CA, United States, 90024
- Website
- www.niagenbioscience.com
- Phone
- 310 388 6706
- IPO / Founded
- 2008-07-15
- Sector
- Healthcare
- Industry
- Biotechnology